This year's principal leaders in the sector are as follows: Geron Corporation (NASDAQ;GERN), Advanced Cell Technology (OTC:ACTC), International Stem Cell Corp. (OTC:ISCO), Pluristem Therapeutics Ltd. (Nasdaq:PSTI), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Mesoblast limited (ASX:MSB) Pfizer Inc. (Public, NYSE:PFE) and Novartis AG (ADR) (Public, NYSE:NVS).
Online PR News – 17-May-2011 – – The emerging regenerative medicine sector is heating up. Investor Stem Cell (www.investorstemcell.com) is the world’s only online discussion forum dedicated to regenerative medicine bringing investors and stakeholders together.
Advanced Cell Technology (OTC:ACTC) Currently has two FDA approved trials using (RPE) cells derived from human embryonic stem cells to treat age related macular degeneration and juvenile MD. Issued patent for non-destructive method of harnessing stem cells without destroying the human embryo.
Geron Corporation (NASDAQ;GERN) Geron is the regenerative sector research Goliath. They are the first company approved by the FDA to use (hESC) to derive its drug GRNOP-1 to treat spinal cord injury. Pipeline of stem cell research consist of cancer, cardio and vascular disease.
International Stem Cell Corp. (OTC:ISCO) Specializing in biomedical research and cosmeceutical products designed to improve skin elasticity, which has been well received in Asia and Japan.
Pluristem Therapeutics Ltd. (Nasdaq:PSTI) Derives their products from human placenta. They specialize in the treatment of several severe degenerative, ischemic and autoimmune disorders; primarily focused on wound healing and orthopedic injuries.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) A global pharmaceutical and drug company. Executive management has an eye for the future of medicine. Teva to acquire Cephalon in $6.8 Billion transaction which will provide shareholders with the safety of revenue in today’s healthcare whilst remaining on the cutting edge of regenerative medicine using stem cells.
Mesoblast limited (ASX:MSB) Specializing in commercial applications of (iPSC), with a culture and scale-up of adult stem cells referred to as Mesenchymal Precursor Cells. Focused on orthopedic segment and the cardiovascular segment. Partnered with Cephalon in late 2010. Well financed and positioned as the leader in adult stem cells.
Pfizer Inc. (Public, NYSE:PFE) Research-based, global biopharmaceutical company. The Company operates in two segments: Biopharmaceutical and Diversified. With an eye towards profits, they use (iPSC) cells to identify potentially dangerous side effects from drugs under development before they undergo expensive human trials.
Novartis AG (ADR) (Public, NYSE:NVS) Operates in four divisions: pharmaceuticals, vaccines and diagnostics, sandoz, and consumer health. Pouring billions of dollars into China healthcare and it is paying off. First Big Pharma to enter the (hESC) field.
Sai Rosen, Director of Client Relations for Investor Stem Cell, commented, “These companies are forging ahead to become the regenerative medicine leaders through their investments in regenerative medicine.”
Disclosure: Stem Cell Media LLC nor its Companies was compensated by “any” entity for this article. www.investorstemcell.com is bringing investors and stakeholders together to participate in the world’s only online discussion forum dedicated to regenerative medicine